U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07940400) titled 'Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer' on Nov. 09.
Brief Summary: Management of prostate cancer increasingly integrates conventional clinicopathologic risk factors with multiparametric magnetic resonance imaging (mpMRI), targeted and systematic biopsy, molecular imaging, and selected tissue-based genomic biomarkers. Contemporary guidelines emphasize risk-adapted shared decision-making and allow selective use of tissue-based genomic biomarkers when additional risk stratification may alter management discussions.
Study Start Date: Dec., 2026
Study Type: OBSERVATIONAL
Condition:...